News

benzinga_article
2026.01.05 19:47
Gyre Therapeutics shares are trading higher after its subsidiary, Gyre Pharmaceuticals, completed a Pre-NDA meeting with China's CDE on its anti-fibrotic therapy Hydronidone. The company plans to submit an NDA in the first half of 2026 and launch a confirmatory clinical trial to support full approval in China.
Source: benzinga_article The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2026 Longbridge｜Disclaimer